STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1 L3, P3 L8	Title, Abstract-Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P3 L2-L7, P4 L7-10	Abstract-Background,
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	P5 L8-P6 L4	Introduction/2
Objectives	3	State specific objectives, including any prespecified hypotheses	P6 L4-8	Introduction/2
Methods				
Study design	4	Present key elements of study design early in the paper	P6 L13-P7 L6	Methods-Subjects
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P6 L13-P7 L6	Methods-Subjects
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	P6 L13-P7 L6	Methods-Subjects
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N.A (control group was not set)	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6 L16-P7 L4	Table 1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P7 L13-P8 L8	Methods-Assessment of serum IgG level
Bias	9	Describe any efforts to address potential sources of bias	P9 L1-L2	Methods-Statistical
Study size	10	Explain how the study size was arrived at	P9 L4-L7	Methods-Statistical
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P7 L13-P8 L8	Methods-Assessment of serum IgG level

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P8 L16-P9 L4	Methods-~Statistical
		(b) Describe any methods used to examine subgroups and interactions	N.A (no subgroups)	
		(c) Explain how missing data were addressed	P7 L4-6	Methods-Subjects
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N.A (not applicable)	
		(e) Describe any sensitivity analyses	N.A (not applicable)	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P9 L11-16	Results-Patient characteristics/Figure 1
		(b) Give reasons for non-participation at each stage	P9 L11-16	Results-Patient
		(c) Consider use of a flow diagram	P9 L11-P10 L13	Results-Patient
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P9 L11-P10 L13	Results-Patient characteristics/Figure 1/Table 1
		(b) Indicate number of participants with missing data for each variable of interest	P9 L11-P10 L13	Results-Patient
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	P7 L6-8	Methods-Effect of
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	P11 L8-17	Results-Effect of IVIG
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N.A (not applicable)	
		Cross-sectional study—Report numbers of outcome events or summary measures	N.A (not applicable)	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P11 L8-17	esults-Effect of IVIG administration on 28-day
		(b) Report category boundaries when continuous variables were categorized	N. A(not categorized)	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N.A (not assess the risk)	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N.A (no subgroup, not	
Discussion				
Key results	18	Summarise key results with reference to study objectives	P12 L2-P14 L14	Discussion/1-3
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P14 L18-P15 L10	Discussion/5

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P14 L18-P15 L10	Discussion/5
Generalisability	21	Discuss the generalisability (external validity) of the study results	P14 L18-P15 L10	Discussion/5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA	NA

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information:https://dx.doi.org/10.21037/apm-21-3694
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.